Life Sciences IP Due Diligence – Assessing, Valuing, and Commercializing IP Assets for the Life Sciences Industry
November 14 - 15, 2019
OMNI Parker House, Boston, MA
CLICK HERE TO REGISTER NOW - Save an extra 10% off* the current rate by using code D10-999-JDS20
Customer Service: 888-224-2480
BMS and Celgene recently announced that their merger would move forward as planned as news broke of Amgen’s $13.4 billion purchase of Celgene’s Otezla. This sale was pivotal to the BMS/Celgene merger due to antitrust concerns raised by the FTC over BMS having a similar product in the pipeline. This move signifies the importance of conducting comprehensive IP due diligence regardless of the size of the deal or type of review – systematic and proficient IP due diligence at the right time is critical for minimizing risk in transactions.
It also signifies the importance of attending ACI's 3rd Annual Summit on Life Sciences IP Due Diligence.
The complete agenda is now available - download the brochure here »
This year’s forum will operate as a think tank and allow you to:
 |
 |
 |
 |
TAILOR
your life sciences IP due diligence checklist for 2020 |
LEARN
firsthand from industry thought leaders on how to perfect the FTO search |
ANALYZE
the latest filings, rulings and legislative developments impacting life sciences IP due diligence |
DEVELOP
strategies for assessing, valuing and commercializing IP assets |
Obtain insights from key industry stakeholders, including:
- Akebia Therapeutics
- Alexion Pharmaceuticals
- Aptevo Therapeutics
- Boehringer Ingelheim USA
- Celgene
- Codiak BioSciences
- Dana-Farber Cancer Institute
- Eisai
- Eli Lilly and Company
- Fortress Investment Group
|
- Fresenius Kabi USA
- Johnson & Johnson Innovation
- Kintai Therapeutics
- Novartis Institutes for Biomedical Research (NIBR)
- Parabellum Capital
- Pfizer Inc.
- Roche
- Stryker
- Takeda Pharmaceutical
- Wave Life Sciences
|
Also, maximize your knowledge by attending our workshops:
PRE-CONFERENCE WORKSHOP
IP Due Diligence 101: Managing the IP Due Diligence Process from Soup to Nuts
POST-CONFERENCE WORKSHOP
Negotiating and Drafting Masterclass: Considerations for Structuring the Deal and the Relevant Documents Post-IP Due Diligence
A WORD FROM OUR CO-CHAIRS
|
Donna M. Meuth
Associate General Counsel Intellectual Property
Eisai Inc.
|
“I’m excited to Co-Chair ACI’s Life Sciences IP Due Diligence conference in Boston this year. The conference offers a great opportunity to gain advice from experts in the field and learn how to avoid issues and mitigate risk in IP due diligences. It’s great to have a conference aimed specifically to the life sciences in view of the many complexities that arise in our transactions.” |
|
Timothy Witkowski
Global Head, Chemistry Patents
Novartis Institutes for BioMedical Research (NIBR)
|
“M&A and licensing practice tests the skills of IP attorneys with novel and difficult issues. I am pleased to Co-Chair ACI’s Life Sciences IP Due Diligence conference because it is a great resource for those who practice in this area by focusing on that crucial piece of any life science company’s strategy: how to properly identify, value, and leverage IP through a potential transaction with another party.” |
Meet all the speakers and learn more about this conference »
REGISTER NOW and save an extra 10% off* the conference by using code D10-999-JDS20
*Discount is valid for new registration only and it’s not applicable for workshops.
